ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Novel and Robust Prognostic Model for Hepatocellular Carcinoma Based on Enhancer RNAs-Regulated Genes

Zhang, Wei; Chen, Kegong; Tian, Wei; Zhang, Qi; Sun, Lin; Wang, Yupeng; Liu, Meina*; Zhang, Qiuju*哈尔滨医科大学; 1
Frontiers in Oncology2022-5-12DOI: 10.3389/fonc.2022.849242
1被引5阅读
引用收藏
分享

摘要

Evidence has demonstrated that enhancer RNAs (eRNAs) play a vital role in the progression and prognosis of cancers, but few studies have focused on the prognostic ability of eRNA-regulated genes (eRGs) for hepatocellular carcinoma (HCC). Using gene expression profiles of HCC patients from the TCGA-LIHC and eRNA expression profiles from the enhancer RNA in cancers (eRic) data portal, we developed a novel and robust prognostic signature composed of 10 eRGs based on Lasso-penalized Cox regression analysis. According to the signature, HCC patients were stratified into high- and low-risk groups, which have been shown to have significant differences in tumor immune microenvironment, immune checkpoints, HLA-related genes, DNA damage repair-related genes, Gene-set variation analysis (GSVA), and the lower half-maximal inhibitory concentration (IC50) of Sorafenib. The prognostic nomogram combining the signature, age, and TNM stage had good predictive ability in the training set (TCGA-LIHC) with the concordance index (C-index) of 0.73 and the AUCs for 1-, 3-, and 5-year OS of 0.82, 0.77, 0.74, respectively. In external validation set (GSE14520), the nomogram also performed well with the C-index of 0.71 and the AUCs for 1-, 3-, and 5-year OS of 0.74, 0.77, 0.74, respectively. In addition, an important eRG (AKR1C3) was validated using two HCC cell lines (Huh7 and MHCC-LM3) in vitro, and the results demonstrated the overexpression of AKR1C3 is related to cell proliferation, migration, and invasion in HCC. Altogether, our eRGs signature and nomogram can predict prognosis accurately and conveniently, facilitate individualized treatment, and improve prognosis for HCC patients.

学科与关键词

关键词
hepatocellular carcinomaenhancer RNAssignatureprognosis
相关
加载中…
  • A New Prognostic Strategy Based on four DNA Repair-Associated lncRNAs for Hepatocellular Carcinoma
    Zeng, Hanyi; Liu, Chengdong; Zhou, Xiaohan; Liu, Li*COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2022, 25(5): 906-918.被引 4
  • Prognosis of colon cancer patients based on enhancer RNAs-related genes
    Han, Xinhao; Tian, Wei; Sun, Lin; Wang, Hongying; Li, Yan; Jia, Huixun; Gao, Guohong; Mai, Liudan; Yin, Shuwen; Zhang, Qiuju*; Liu, Yanlong*Journal of Cancer Research and Clinical Oncology, 2023, 149(13): 12443-12457.
  • Inflammatory Response-Related Long Non-Coding RNA Signature Predicts the Prognosis of Hepatocellular Carcinoma
    Li, Xinyu; Zhang, Shuqiao; Zhang, Shijun; Kuang, Weihong; Tang, Chunzhi*Journal of Oncology, 2022, 2022: 9917244.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-05-12
卷期
第 12 卷
页码
849242
DOI
10.3389/fonc.2022.849242
期刊等级
3区
成果收录
SCIE

作者

  • Z

    Zhang, Wei (第一作者)

    harbin med univ

  • C

    Chen, Kegong

    2 · harbin med univ · 1 · univ sci & technol china · ustc

查看全部 8 位作者收起作者
  • T

    Tian, Wei

    harbin med univ

  • Z

    Zhang, Qi

  • S

    Sun, Lin

    harbin med univ

  • W

    Wang, Yupeng

    harbin med univ

  • L

    Liu, Meina (通讯)

    harbin med univ

  • Z

    Zhang, Qiuju (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417